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Background
TRAIL is present in cells involved in asthma including
eosinophils, mast cells, fibroblasts, and airway epithelial
cells. It is expressed in airway remodeling and may be
linked with the pathways of transforming growth factor-
beta1, which is thought to cause damage to the epithelium.
The repair process of the epithelium is hindered as a result
of increased apoptosis induced by TGF-beta1, which over-
laps with the pathways of TRAIL. Analogs of TRAIL could
have therapeutical applications for asthma. TRAIL is also
seen as the basis for a “miracle” drug for cancer because of
its ability to selectively kill cancer cells. Allergic rhinitis is
a common health problem affecting the immune system.
The homeostasis of the immune system is regulated by
apoptosis. In this study, serumcirculating soluble TRAIL
levels of allergic rhinoconjunctivitis patients before aller-
gen-specific immunotherapy and after the treatment was
evaluated.
Methods
Subjects with kidney disease, heart disease, liver disease,
diabetes mellitus, cancer status, obesity, (body mass index
(BMI) ≥ 30 kg.m2) and autoimmune disease were excluded
clinically and serologically. The sTRAIL levels of pre- and
post-treated allergic rhinoconjunctivitis patients (n=25)
were compared to age and sex-matched healthy individuals
(n=25). sTRAIL levels were measured by ELISA. The skin
prick test (SPT) were recorded before and after treatment.
Results
The sTRAIL levels between the pre-treated and control
groups were significantly different (p < 0,0001). However,
there was no significant difference between post-treated
group and healthy individuals (p = 0,801). SPT was a sta-
tistically significant difference between the values of the
research group before and after immunotherapy (Grasses
mixture, Barley mixture, Oleaauropeae, D. Pteronyssinus,
D. farinae).
Conclusions
Allergen- spesific immunotherapy treatment significantly
reduced the nasal symptom score across all group I
patients studied . In this study, SPT was a statistically
significant difference between the values of the research
group before and after immunotherapy (Grasses mixture,
Barley mixture, Oleaauropeae, D.Pteronyssinus, D. farinae).
The sTRAIL levels were decreased after allergen-specific
immunotherapy as to healthy individuals’ levels. be a mar-
ker of efficacy of immunotherapy in allergic rhinoconjuncti-
vitis patients.
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